Webinar

Treating Blindness with Stem Cell Therapies

— With Dr. Laura Koivusalo, Professor Dr. Anders Kvanta, Dr. Fredrik Lanner, Dr. Stijn Heessen, Dr. Kristian Tryggvason, MBA and Dr. Susanna Teppo —

Highlights:

• We need (more) basic research and a broad approach
  Several clinical trials show PSC therapies are safe, with early signs of long-term benefit — including promising follow-up data for LSCD. However, major challenges remain. Academic research is critical to better understand disease mechanisms, improve biomaterials for transplantation, and standardize cell identity markers.
  
• Translating cell production from the lab to the clinic requires precision
  Eye diseases are complex, and stem cell therapies are among the most advanced treatments being developed. Achieving GMP compliance and consistent manufacturing takes time and strategic planning. Starting with the end in mind is essential.
  
• The cost of PSC therapies remain high, but there is optimism for the future
  PSC therapies are still expensive, and investor and reimbursement incentives must be addressed early. Encouragingly, advances such as automation are paving the way for more scalable and cost-effective production.